Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts give Mirum a consensus "Moderate Buy" rating from 14 brokerages (1 sell, 12 buy, 1 strong buy) with an average 12‑month price target of $121.33.
• Mirum missed on EPS, reporting ($0.11) vs. $0.02 expected while beating revenue at $148.93M (up ~49.8% YoY); the company still shows negative margins and analysts forecast about -1.77 EPS for the year.
• Insiders have been selling: CEO Christopher Peetz and director Joanne Quan sold shares on March 16, and insiders disposed of 89,513 shares (~$8.38M) over the past 90 days, though insiders still own 22.87% of the stock.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has received a consensus rating of "Moderate Buy" from the fourteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $121.3333.

A number of brokerages have weighed in on MIRM. Evercore set a $126.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, March 4th. Wall Street Zen downgraded shares of Mirum Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, February 28th. Citizens Jmp reaffirmed a "market outperform" rating and set a $132.00 target price on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 21st. Stifel Nicolaus raised their target price on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Finally, Leerink Partners decreased their target price on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an "outperform" rating for the company in a research note on Thursday, February 26th.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $94.00 on Wednesday. Mirum Pharmaceuticals has a 1 year low of $40.00 and a 1 year high of $109.28. The company has a market cap of $5.73 billion, a P/E ratio of -195.83 and a beta of 0.51. The firm has a 50-day moving average of $94.16 and a 200 day moving average of $85.07. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The company had revenue of $148.93 million during the quarter, compared to the consensus estimate of $141.78 million. During the same period in the previous year, the company earned $1.00 earnings per share. Mirum Pharmaceuticals's quarterly revenue was up 49.8% on a year-over-year basis. On average, sell-side analysts forecast that Mirum Pharmaceuticals will post -1.77 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, insider Joanne Quan sold 7,287 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the transaction, the insider owned 18,864 shares of the company's stock, valued at approximately $1,735,110.72. This trade represents a 27.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Christopher Peetz sold 40,985 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the sale, the chief executive officer directly owned 194,309 shares of the company's stock, valued at $17,872,541.82. This trade represents a 17.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 89,513 shares of company stock valued at $8,377,249. 22.87% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Faithward Advisors LLC increased its position in shares of Mirum Pharmaceuticals by 0.5% during the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company's stock valued at $2,537,000 after acquiring an additional 126 shares in the last quarter. CWM LLC increased its position in shares of Mirum Pharmaceuticals by 30.8% during the third quarter. CWM LLC now owns 683 shares of the company's stock valued at $50,000 after acquiring an additional 161 shares in the last quarter. MCF Advisors LLC increased its position in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company's stock valued at $31,000 after acquiring an additional 185 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of Mirum Pharmaceuticals by 6.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company's stock valued at $253,000 after acquiring an additional 200 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its position in shares of Mirum Pharmaceuticals by 34.0% during the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company's stock valued at $70,000 after acquiring an additional 243 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.